PART 3: What’s Next in 2018? Advanced Therapeutics – Gene Therapy, CAR-T, and Microbiome

PART 2: 2018 Wildcards – Healthcare Regulation and Models of Care

PART 1: Reflections on 2017 – Biopharma Therapeutics

Who’s Really First in FDA Cleared Digital Therapeutics?

Beyond Traditional Drug Development: Leveraging Personalized Medicine

Towards a Treatment for the Next Big Liver Disease

Strategies to Best Capitalize Accelerated Pathways for Innovative Medicines in the 21st Century

Drug Price Increases-Undue Pricing Power or Supported by Competitive Marketplace?

Beyond Turing and Valeant- Why is Drug Pricing Such a Hot Issue?

How Much Longer Before Biopharma Embraces Remote Monitoring in Clinical Trials?

CAR-T: The Emperor’s New Clothes or The Second Coming?

Juno Therapeutics and Celgene Ink 10 Year Deal

Drug Pricing & Reimbursement at the Boston CMO Network

Health Advances at ADA: Industry Forum Panel “Embracing the Future of Open Data Sharing”

BIO 2015: New Name, New Challenges

Pricing Orphan and Specialty Drugs-Insights from the World Orphan Drug Congress & ISPOR

The Health Evolution Summit Report Published

Insights from the T1D Exchange Annual Meeting

The Helmsley Trust Awards $8.7M funding for T1D Research

Health Advances Blog

Category: BioPharma

PART 3: What’s Next in 2018? Advanced Therapeutics – Gene Therapy, CAR-T, and Microbiome

PART 2: 2018 Wildcards – Healthcare Regulation and Models of Care

PART 1: Reflections on 2017 – Biopharma Therapeutics

Who’s Really First in FDA Cleared Digital Therapeutics?

Beyond Traditional Drug Development: Leveraging Personalized Medicine

Towards a Treatment for the Next Big Liver Disease

Strategies to Best Capitalize Accelerated Pathways for Innovative Medicines in the 21st Century

Drug Price Increases-Undue Pricing Power or Supported by Competitive Marketplace?

Beyond Turing and Valeant- Why is Drug Pricing Such a Hot Issue?

How Much Longer Before Biopharma Embraces Remote Monitoring in Clinical Trials?

CAR-T: The Emperor’s New Clothes or The Second Coming?

Juno Therapeutics and Celgene Ink 10 Year Deal

Drug Pricing & Reimbursement at the Boston CMO Network

Health Advances at ADA: Industry Forum Panel “Embracing the Future of Open Data Sharing”

BIO 2015: New Name, New Challenges

Pricing Orphan and Specialty Drugs-Insights from the World Orphan Drug Congress & ISPOR

The Health Evolution Summit Report Published

Insights from the T1D Exchange Annual Meeting

The Helmsley Trust Awards $8.7M funding for T1D Research